^
Association details:
| Biomarker: | ERBB3 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Excerpt:
In the growth inhibition assay, all colorectal cancer cell lines were sensitive to DXd. In the tumor xenograft model, significant tumor regression with U3-1402 was observed both in the DiFi cell line (high HER3 expression; KRAS wild type) and in SW620 (high HER3 expression; KRAS mutation), but no treatment effect was observed in Colo320DM (low HER3 expression)...The antitumor activity of U3-1402 was dependent on HER3 expression level, but not on KRAS mutation status.
DOI:
10.1158/1535-7163.MCT-19-0452
